Skip to main content

Author: Bill Snyder

Personalized Structural Biology aids cancer treatment decisions

Apr. 8, 2021—Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

Read more


Health care quality expert Berwick set for Discovery Lecture

Apr. 7, 2021—Donald Berwick, MD, MPP, one of the nation’s leading authorities on health care quality and improvement, will deliver the next web-based Discovery Lecture on Thursday, April 15, at 4 p.m. via Zoom.

Read more


U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC

Apr. 6, 2021—The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.

Read more


Investigational vaccine to be tested against COVID-19 variant

Apr. 2, 2021—Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.

Read more


Novel way to neutralize Rift Valley Fever Virus

Apr. 1, 2021—The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

Read more


Study shows new COVID target could improve vaccines

Apr. 1, 2021—Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.

Read more


Physician-scientists Aliyu, Tindle elected to ASCI

Mar. 31, 2021—Vanderbilt’s Muktar Aliyu, MBBS, MPH, DrPH, and Hilary Tindle, MD, MPH, will be inducted this year into the American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry.

Read more


Study to assess allergic reactions to COVID vaccines

Mar. 18, 2021—Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.

Read more


‘Friendly’ bacteria may impact COVID severity

Mar. 11, 2021—The U.S. Centers for Disease Control and Prevention (CDC) has awarded Vanderbilt University Medical Center a two-year, $3.7-million contract to determine genetic and bacterial factors that may increase the risk for severe illness and death from COVID-19.

Read more


Discovery Lecture to feature geriatric medicine expert Cassel

Mar. 11, 2021—Christine Cassel, MD, a leading expert in geriatric medicine, medical ethics and the quality of care, will deliver the next web-based Discovery Lecture on Thursday, March 25, at 4 p.m. via Zoom.

Read more


Monoclonal antibody “cocktail” blocks COVID-19 variants: study

Mar. 4, 2021—A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.

Read more


Chikungunya antibody identified at VUMC moves forward

Mar. 4, 2021—Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more